Oncology Institute (TOIIW) Cost of Revenue (2021 - 2026)

Oncology Institute has reported Cost of Revenue for 6 years, with the latest figure at $8.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue fell 73.65% year-over-year to $8.3 million; the trailing twelve-month figure through Mar 2026 stood at $74.9 million (up 881.52% YoY), and the FY2025 full-year result was $220.6 million, up 16813.96% from the prior year.
• Cost of Revenue for Q1 2026 stood at $8.3 million, down from $66.5 million in the prior quarter.
• The five-year high for Cost of Revenue was $66.5 million in Q4 2025, with the low at -$110.4 million in Q4 2024.
• Historically, Cost of Revenue has averaged $22.5 million across 5 years, with a median of $34.5 million in 2022.
• Annual changes were most pronounced in 2023 — Cost of Revenue soared 40886.44% — and 2024, when it tumbled 328.26%.
• Oncology Institute's Cost of Revenue stood at $118000.0 in 2022, then soared by 40886.44% to $48.4 million in 2023, then slumped by 328.26% to -$110.4 million in 2024, then soared by 160.27% to $66.5 million in 2025, then sank by 87.56% to $8.3 million in 2026.
• The last three Cost of Revenue figures came in at $8.3 million (Q1 2026), $66.5 million (Q4 2025), and $65000.0 (Q2 2025), per Business Quant data.